28 April 2025
: Case report 
Post-COVID-19 Guillain-Barré Syndrome with GM1 and GD1b Antibodies: A Case Study and Literature Review
Rare coexistence of disease or pathology
Mrudula Thiriveedi
ABDE 1*, Francis G. Sto. Domingo BDF 2, Sawyer Longley BDF 2, Siddharth Patel DE 1, Sujatha Baddam DEF 3, Anil Chimakurthy DEF 4
DOI: 10.12659/AJCR.947416
Am J Case Rep 2025; 26:e947416
Table 1 Comparison of post-COVID-19 GBS cases with anti-GM1 antibodies.
| Authors | Age, Sex (M/F) | Days to onset of neurological symptoms after COVID-19 infection | Treatment received | Outcome | Anti-ganglioside antibodies reported |
|---|---|---|---|---|---|
| Petrelli et al []20 | 57-year-old, Male | 17 days | IVIG 400 mg/kg/day, dexamethasone 500 mg/day for 5 days | Slight improvement in distal upper limb strength with persistent strength deficit in the lower extremities | GM1, GD1a |
| Civadri et al []21 | 72-year-old, Female | 10 days | IVIG, hydroxychloroquine, doxycycline hyclate | Muscle strength improved to 4/5 in the upper extremities and to 3/5 in the lower extremities; respiratory support still needed | GM1, GD1a, GD1b |
| Dufour et al []15 | 36-year-old, Female | 21 days | IVIG 400 mg/kg/day | Resolution of symptoms after 5 days of IVIG. The patient reported walking short distances 3 weeks after discharge | GM1, GD1b, GQ1b, Asialo GM1, GD1a |
| Thiriveedi et al (our case) | 86-year-old, Male | 28 days | IVIG 400 mg/kg/day 2 rounds of 5 days each | Minimal improvement of strength in bilateral upper and lower extremities | GM1, GD1b |